Liqibur 0.5 mg (Entecavir Hydrate)

Adult dose

Administer this medication orally on an empty stomach (2 hours after a meal or at least 2 hours before a meal). Administer entecavir 0.5mg orally once daily. Patients with lamivudine resistance, i.e., patients aged 16 years or older who have experienced persistent replication of hepatitis B virus despite lamivudine treatment or who have lamivudine-resistant mutations: Administer entecavir 1mg once daily on an empty stomach. Patients with renal impairment: In patients with renal impairment, the oral clearance of this medication decreases as creatinine clearance decreases. For patients with creatinine clearance below 50mL/min, including those receiving hemodialysis or peritoneal dialysis (CAPD), adjust the dose as follows. Creatinine clearance (mL/min) | Entecavir dose | Entecavir dose in patients with lamivudine resistance ≥ 50 | 0.5 mg once daily | 1 mg once daily 30 - <50 | 0.25 mg once daily a or 0.5 mg every 48 hours | 0.5 mg once daily or 1 mg every 48 hours 10 - <30 | 0.15 mg once daily a or 0.5 mg every 72 hours | 0.3 mg once daily a or 1 mg every 72 hours <10, hemodialysis b or CAPD | 0.05 mg once daily a or 0.5 mg every 7 days | 0.1 mg once daily a or 1 mg every 7 days a: For doses below 0.5mg, use of the syrup formulation is recommended. b: If administered on a hemodialysis day, administer this medication after the hemodialysis session. (Pharmacokinetic properties in patients with renal impairment: Refer to “8. Administration to patients with renal impairment” under Precautions for Use.)

Child dose

Applicable to patients aged 16 and older who are resistant to lamivudine, specific dosing guidelines for children are not specified.

Caution is required when administering this medication to patients with liver disease. Especially, patients with severely impaired liver function or decreased kidney function may require dosage adjustment. This medication can cause serious side effects such as liver dysfunction or lactic acidosis, so liver function tests and clinical symptoms should be monitored regularly during treatment. Additionally, abrupt discontinuation of this medication can lead to rapid deterioration of hepatitis B, so discontinuation must be done under a doctor's guidance. This medication is not recommended for HIV-infected patients who are not receiving antiretroviral therapy, and it is important to perform an HIV test before administration. Patients with hypersensitivity to this medication or certain genetic disorders such as lactose intolerance should not take this medication. Pregnant women should carefully consider the risks to the fetus and the benefits of use, while breastfeeding women are advised to discontinue breastfeeding or stop the medication. Taking this medication with food can reduce absorption, so it is best taken on an empty stomach. Patients with decreased kidney function may have accumulation of this medication in the body, hence periodic monitoring of kidney function and possible dosage adjustment may be necessary. This medication may interact with other drugs, especially when taken with medications that affect kidney function, so consultation with a doctor or pharmacist is essential. Long-term use of this medication may lead to the development of resistance, therefore, regular tests should be conducted to evaluate the treatment efficacy. Furthermore, this medication may be administered to children and elderly patients, but careful management should be considered based on age-related physical condition and kidney function. In case of overdose, immediate consultation with medical personnel is necessary, and treatments such as hemodialysis may be required. Finally, it is important to keep this medication out of the reach of children, away from direct sunlight, and stored at room temperature.

Lactic acidosis, fatty liver, liver enlargement, liver metabolic dysfunction, headache, fatigue, dizziness, nausea, diarrhea, indigestion, vomiting, vertigo, drowsiness, insomnia, anaphylactic reaction, increased aminotransferase levels, hair loss, rash, upper abdominal pain, heartburn, chest pain, cold, cough, itching, constipation, abdominal pain, back pain, abdominal discomfort, runny nose, intra-abdominal hemorrhage, ascites, portal hypertension-related gastric disease, gastrointestinal bleeding, cholangitis, hepatic encephalopathy, septal deviation, sepsis, eyelid skin disease, gastric vascular lesion, chronic sinusitis, abdominal pain, rash, unpleasant taste, neutropenia

This medication should be stored in a tightly sealed container to prevent air and moisture from entering, and the storage temperature should be maintained between 15 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication and prevent deterioration.

Appearance

White to grayish-white triangular film-coated tablets

Package unit

30 tablets (10 tablets/Alu-Alu × 3)